07.12.16
MilliporeSigma has entered into an agreement with PCAS S.A. of Longjumeau, France to be the exclusive, global distributorof PCAS’Expansorb line of biocompatible and biodegradable polymers.
The portfolio will include 38 polymers for sustained release of small molecule and selected peptide injectables, allowing customers to optimize and control release kinetics of final drug products. The ability to better control and sustain the release of drugs allows for delivery via reduced numbers of injections with the same therapeutic efficacy.
"The pharmaceutical industry is increasingly interested in controlling the release of small molecules and selected peptides delivered via injection," said Andrew Bulpin, head of process solutions at MilliporeSigma. "The addition of the Expansorb® polymers to our broad portfolio of excipients improves drug developers' ability to protect molecules with short in vivo half-lives and achieve the desired therapeutic effect while enhancing patient comfort and compliance."
Poly lactic acid (PLA) and poly lactic-co-glycolic acid (PLGA) polymers are biocompatible and biodegradable synthetic substances that have been approved by the U.S. FDA and the EMA with several drug products on the market and many others in development.
Expansorb PLA and PLGA polymers are manufactured under cGMP conditions by PCAS and are expected to be sold under MilliporeSigma's Emprove program following evaluations and certifications.
The portfolio will include 38 polymers for sustained release of small molecule and selected peptide injectables, allowing customers to optimize and control release kinetics of final drug products. The ability to better control and sustain the release of drugs allows for delivery via reduced numbers of injections with the same therapeutic efficacy.
"The pharmaceutical industry is increasingly interested in controlling the release of small molecules and selected peptides delivered via injection," said Andrew Bulpin, head of process solutions at MilliporeSigma. "The addition of the Expansorb® polymers to our broad portfolio of excipients improves drug developers' ability to protect molecules with short in vivo half-lives and achieve the desired therapeutic effect while enhancing patient comfort and compliance."
Poly lactic acid (PLA) and poly lactic-co-glycolic acid (PLGA) polymers are biocompatible and biodegradable synthetic substances that have been approved by the U.S. FDA and the EMA with several drug products on the market and many others in development.
Expansorb PLA and PLGA polymers are manufactured under cGMP conditions by PCAS and are expected to be sold under MilliporeSigma's Emprove program following evaluations and certifications.